Nordic Nanovector And Affibody Collaborate On Advanced Radio-Immunotherapies Program For Multiple Myeloma

OSLO, Norway & SOLNA, Sweden--(BUSINESS WIRE)--Nordic Nanovector ASA and Affibody AB today announced that the companies have entered into a three-year collaborative research agreement to discover and develop new advanced radio-immunotherapies (RIT) for multiple myeloma. Backed by a Eurostars grant the project will combine Affibody’s proprietary platforms with Nordic Nanovector's radioimmunotherapy technology. The project aims to provide documentation necessary to start GMP manufacturing of the Affibody®-based RIT and subsequently start clinical trials. The companies have been awarded approximately €1m in total by Vinnova in Sweden and The Norwegian Research Council in Norway.

Help employers find you! Check out all the jobs and post your resume.

Back to news